Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...

The about-$1 billion deal could come imminently.

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

BioAge LabsBIOA shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, a ...

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

LifeSci Capital analyst Sam Slutsky maintained a Hold rating on Ventyx Biosciences yesterday and set a price target of $14.00.

Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...